Wall Street analyst estimates for Cumberland Pharmaceuticals Inc. (CPIX): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Cumberland Pharmaceuticals Inc. functions as a specialized pharmaceutical enterprise, primarily involved in the procurement, advancement, and commercialization of prescription medications. Its strategic focus areas include acute hospital care, gastroenterology, rheumatology, and oncology, with operations spanning both the United States and global markets. The company's existing product line includes: Acetadote: an injectable solution for treating acetaminophen poisoning.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.13 | ||
| 2026-08-04 | $-0.20 | $-0.13 | -53.8% |
| 2026-05-05 | $-0.13 | $-0.13 | +0.0% |
| 2026-03-03 | $-0.01 | $-0.13 | +92.3% |
| 2025-11-04 | $-0.06 | $-0.13 | +53.8% |
| 2025-08-05 | $0.02 | ||
| 2025-05-06 | $0.16 | $-0.01 | +1700.0% |
| 2025-03-04 | $-0.02 | $-0.11 | +81.8% |
Valuation Ratios
| Price / Book | 6.05 |
| EV / EBITDA | -17.72 |
| Dividend Yield | 21.30% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $33.0M | $41.2M | $40.7M | $34.4M | $37.4M | $36.0M | $42.0M | $39.6M | $37.9M | $44.5M |
| Cost of Revenue | $6.0M | $7.4M | $7.4M | $7.4M | $8.7M | $8.8M | $9.1M | $6.1M | $6.6M | $6.7M |
| Gross Profit | $27.1M | $33.8M | $33.4M | $27.0M | $28.8M | $27.2M | $32.9M | $33.5M | $31.3M | $37.9M |
| Research & Development | $3.2M | $3.9M | $7.3M | $6.9M | $5.8M | $5.7M | $6.7M | $5.8M | $4.8M | $5.6M |
| Selling, General & Admin | $23.1M | $31.5M | $30.7M | $25.3M | $25.0M | $24.8M | $26.8M | $29.1M | $28.1M | $31.0M |
| Operating Expenses | $28.5M | $37.9M | $40.8M | $36.3M | $35.2M | $34.9M | $38.6M | $43.0M | $37.7M | $40.6M |
| Operating Income | -$1.4M | -$4.1M | -$7.4M | -$9.3M | -$6.4M | -$7.7M | -$5.7M | -$9.6M | -$6.4M | -$2.8M |
| EBITDA | $1.2M | -$1.1M | -$8.2M | -$4.6M | -$1.6M | -$857833 | $332919 | $2.5M | $182422 | $3.0M |
| Interest Expense | $106392 | $92904 | $195848 | $246186 | $263627 | $98031 | $585995 | $667861 | $605508 | $495990 |
| Pre-tax Income | -$1.3M | -$3.9M | -$7.0M | -$9.3M | -$6.6M | -$5.6M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
| Income Tax | -$330924 | $4.2M | $16636 | -$79316 | $55902 | $34891 | $68850 | $45769 | -$22669 | $40256 |
| Net Income | -$944683 | -$8.0M | -$7.0M | -$3.5M | -$3.3M | -$3.5M | -$5.6M | -$6.3M | -$6.5M | -$2.8M |
| EPS | $-0.06 | $-0.50 | $-0.45 | $-0.23 | $-0.22 | $-0.24 | $-0.38 | $-0.44 | $-0.46 | $-0.19 |
| EPS (Diluted) | $-0.06 | $-0.50 | $-0.45 | $-0.23 | $-0.22 | $-0.24 | $-0.38 | $-0.44 | $-0.46 | $-0.19 |
| Shares Outstanding (Diluted) | $16.2M | $15.9M | $15.6M | $15.4M | $15.2M | $14.9M | $14.6M | $14.3M | $14.1M | $15.0M |
Price
| Price | $6.98 |
| Market Cap | $105M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVC · CALC · CELU · DYAI · LTRN · LVTX · NOTV
Explore sector: Healthcare · Drug Manufacturers - Specialty & Generic
More sections of CPIX: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks